These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14678328)

  • 1. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N
    Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
    Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
    J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L; Löwenadler B; Lycke N
    Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.
    Nedrud JG; Bagheri N; Schön K; Xin W; Bergroth H; Eliasson DG; Lycke NY
    PLoS One; 2013; 8(12):e83321. PubMed ID: 24391754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N; Schön K
    Vaccine; 2001 Mar; 19(17-19):2542-8. PubMed ID: 11257390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N
    Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC; Ekman L; Löwenadler B; Lycke NY
    J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y; Larsson L; Mattsson J; Lycke N; Xiang Z
    J Immunol; 2010 Sep; 185(5):2935-41. PubMed ID: 20675596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
    J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N
    Curr Opin Mol Ther; 2001 Feb; 3(1):37-44. PubMed ID: 11249730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
    Sundling C; Schön K; Mörner A; Forsell MNE; Wyatt RT; Thorstensson R; Hedestam GBK; Lycke NY
    J Gen Virol; 2008 Dec; 89(Pt 12):2954-2964. PubMed ID: 19008380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L; Sverremark E; Ekman L; Schön K; Löwenadler B; Fernandez C; Lycke N
    J Immunol; 2000 Jun; 164(12):6276-86. PubMed ID: 10843681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
    Eriksson AM; Schön KM; Lycke NY
    J Immunol; 2004 Sep; 173(5):3310-9. PubMed ID: 15322194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted vaccine adjuvants based on modified cholera toxin.
    Lycke N
    Curr Mol Med; 2005 Sep; 5(6):591-7. PubMed ID: 16178769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulating complexes (ISCOMs) for nasal vaccination.
    Hu KF; Lövgren-Bengtsson K; Morein B
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):149-59. PubMed ID: 11516786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action.
    Grdic D; Smith R; Donachie A; Kjerrulf M; Hörnquist E; Mowat A; Lycke N
    Eur J Immunol; 1999 Jun; 29(6):1774-84. PubMed ID: 10382739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.